Cortical morphology in patients with the deficit and non-deficit syndrome of schizophrenia: a worldwide meta- and mega-analyses.


Journal

Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835

Informations de publication

Date de publication:
29 Aug 2023
Historique:
received: 20 01 2023
accepted: 07 08 2023
revised: 02 08 2023
medline: 30 8 2023
pubmed: 30 8 2023
entrez: 29 8 2023
Statut: aheadofprint

Résumé

Converging evidence suggests that schizophrenia (SZ) with primary, enduring negative symptoms (i.e., Deficit SZ (DSZ)) represents a distinct entity within the SZ spectrum while the neurobiological underpinnings remain undetermined. In the largest dataset of DSZ and Non-Deficit (NDSZ), we conducted a meta-analysis of data from 1560 individuals (168 DSZ, 373 NDSZ, 1019 Healthy Controls (HC)) and a mega-analysis of a subsampled data from 944 individuals (115 DSZ, 254 NDSZ, 575 HC) collected across 9 worldwide research centers of the ENIGMA SZ Working Group (8 in the mega-analysis), to clarify whether they differ in terms of cortical morphology. In the meta-analysis, sites computed effect sizes for differences in cortical thickness and surface area between SZ and control groups using a harmonized pipeline. In the mega-analysis, cortical values of individuals with schizophrenia and control participants were analyzed across sites using mixed-model ANCOVAs. The meta-analysis of cortical thickness showed a converging pattern of widespread thinner cortex in fronto-parietal regions of the left hemisphere in both DSZ and NDSZ, when compared to HC. However, DSZ have more pronounced thickness abnormalities than NDSZ, mostly involving the right fronto-parietal cortices. As for surface area, NDSZ showed differences in fronto-parietal-temporo-occipital cortices as compared to HC, and in temporo-occipital cortices as compared to DSZ. Although DSZ and NDSZ show widespread overlapping regions of thinner cortex as compared to HC, cortical thinning seems to better typify DSZ, being more extensive and bilateral, while surface area alterations are more evident in NDSZ. Our findings demonstrate for the first time that DSZ and NDSZ are characterized by different neuroimaging phenotypes, supporting a nosological distinction between DSZ and NDSZ and point toward the separate disease hypothesis.

Identifiants

pubmed: 37644174
doi: 10.1038/s41380-023-02221-w
pii: 10.1038/s41380-023-02221-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : RC 23
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : RC 23
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : RF-2019-12370182
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : RC 23
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : RC 23
Organisme : U.S. Department of Veterans Affairs (Department of Veterans Affairs)
ID : 1IK6CX002519
Organisme : Brain and Behavior Research Foundation (Brain & Behavior Research Foundation)
ID : NIH R01 MH076989
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : MH-092443, MH-094268, MH-105660, and MH-107730
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : R01MH116147, R01MH121246, and R01MH129742
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : R01MH117601
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : R01MH116147, R01MH121246, and R01MH129742
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : R21MH097196
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
ID : R01MH121246
Organisme : National Healthcare Group (NHG)
ID : SIG/05004; SIG/05028
Organisme : Ministerstvo Zdravotnictví Ceské Republiky (Ministry of Health of the Czech Republic)
ID : NU21-08-00432; NU20-04-00393
Organisme : Ministerstvo Zdravotnictví Ceské Republiky (Ministry of Health of the Czech Republic)
ID : NU21-08-00432; NU20-04-00393

Informations de copyright

© 2023. The Author(s).

Références

Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58:165–71.
pubmed: 11177118 doi: 10.1001/archpsyc.58.2.165
Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145:578–83.
pubmed: 3358462 doi: 10.1176/ajp.145.5.578
Kirkpatrick B, Mucci A, Galderisi S. Primary, Enduring Negative Symptoms: An Update on Research. Schizophr Bull. 2017;43:730–6.
pubmed: 28575513 pmcid: 5472155 doi: 10.1093/schbul/sbx064
Voineskos AN, Foussias G, Lerch J, Felsky D, Remington G, Rajji TK, et al. Neuroimaging evidence for the deficit subtype of schizophrenia. JAMA Psychiatry. 2013;70:472–80.
pubmed: 23467781 doi: 10.1001/jamapsychiatry.2013.786
López-Díaz Á, Lara I, Lahera G. Is the Prevalence of the Deficit Syndrome in Schizophrenia Higher than Estimated? Results of a Meta-Analysis. Psychiatry Investig. 2018;15:94–8.
pubmed: 29422932 pmcid: 5795038 doi: 10.4306/pi.2018.15.1.94
Strauss GP, Harrow M, Grossman LS, Rosen C. Periods of recovery in deficit syndrome schizophrenia: a 20-year multi-follow-up longitudinal study. Schizophr Bull. 2010;36:788–99.
pubmed: 19095758 doi: 10.1093/schbul/sbn167
Albayrak Y, Akyol ES, Beyazyüz M, Baykal S, Kuloglu M. Neurological soft signs might be endophenotype candidates for patients with deficit syndrome schizophrenia. Neuropsychiatr Dis Treat. 2015;11:2825–31.
pubmed: 26604767 pmcid: 4631425 doi: 10.2147/NDT.S91170
Bora E, Binnur Akdede B, Alptekin K. Neurocognitive impairment in deficit and non-deficit schizophrenia: a meta-analysis. Psychol Med. 2017;47:2401–13.
pubmed: 28468693 doi: 10.1017/S0033291717000952
Boutros NN, Mucci A, Vignapiano A, Galderisi S. Electrophysiological aberrations associated with negative symptoms in schizophrenia. Curr Top Behav Neurosci. 2014;21:129–56.
pubmed: 24671702 doi: 10.1007/7854_2014_303
Goldsmith DR, Haroon E, Miller AH, Strauss GP, Buckley PF, Miller BJ. TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophr Res. 2018;199:281–4.
pubmed: 29499967 pmcid: 6111000 doi: 10.1016/j.schres.2018.02.048
Mucci A, Merlotti E, Üçok A, Aleman A, Galderisi S. Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases. Schizophr Res. 2017;186:19–28.
pubmed: 27242069 doi: 10.1016/j.schres.2016.05.014
Wheeler AL, Wessa M, Szeszko PR, Foussias G, Chakravarty MM, Lerch JP, et al. Further neuroimaging evidence for the deficit subtype of schizophrenia: a cortical connectomics analysis. JAMA Psychiatry. 2015;72:446–55.
pubmed: 25786193 doi: 10.1001/jamapsychiatry.2014.3020
Downs J, Dean H, Lechler S, Sears N, Patel R, Shetty H, et al. Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure. Schizophr Bull. 2019;45:69–79.
pubmed: 29370404 doi: 10.1093/schbul/sbx197
Peralta V, Moreno-Izco L, Sanchez-Torres A, García de Jalón E, Campos MS, Cuesta MJ. Characterization of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs. Schizophr Bull. 2014;40:214–24.
pubmed: 23256987 doi: 10.1093/schbul/sbs152
Arango C, Buchanan RW, Kirkpatrick B, Carpenter WT. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry. 2004;19:21–6.
pubmed: 14969777 doi: 10.1016/j.eurpsy.2003.10.004
Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17:1206–27.
pubmed: 22584864 doi: 10.1038/mp.2012.47
Kirkpatrick B, Gürbüz Oflezer Ö, Delice Arslan M, Hack G, Fernandez-Egea E. An Early Developmental Marker of Deficit versus Nondeficit Schizophrenia. Schizophr Bull. 2019;45:1331–5.
pubmed: 31423529 pmcid: 6811833 doi: 10.1093/schbul/sbz024
Kirkpatrick B, Galderisi S. Deficit schizophrenia: an update. World Psychiatry. 2008;7:143–7.
pubmed: 18836581 pmcid: 2559917 doi: 10.1002/j.2051-5545.2008.tb00181.x
López-Díaz Á, Menéndez-Sampil C, Pérez-Romero A, Palermo-Zeballos FJ, Valdés-Florido MJ. Characterization of deficit schizophrenia and reliability of the bidimensional model of its negative symptomatology. Nord J Psychiatry. 2020;74:400–6.
pubmed: 32149549 doi: 10.1080/08039488.2020.1736151
Ahmed AO, Strauss GP, Buchanan RW, Kirkpatrick B, Carpenter WT. Schizophrenia heterogeneity revisited: Clinical, cognitive, and psychosocial correlates of statistically-derived negative symptoms subgroups. J Psychiatr Res. 2018;97:8–15.
pubmed: 29156414 doi: 10.1016/j.jpsychires.2017.11.004
Cohen AS, Docherty NM. Deficit versus negative syndrome in schizophrenia: prediction of attentional impairment. Schizophr Bull. 2004;30:827–35.
pubmed: 15954193 doi: 10.1093/oxfordjournals.schbul.a007135
Cascella NG, Testa SM, Meyer SM, Rao VA, Diaz-Asper CM, Pearlson GD, et al. Neuropsychological impairment in deficit vs. non-deficit schizophrenia. J Psychiatr Res. 2008;42:930–7.
pubmed: 18021807 doi: 10.1016/j.jpsychires.2007.10.002
Farkas M, Polgár P, Kelemen O, Réthelyi J, Bitter I, Myers CE, et al. Associative learning in deficit and nondeficit schizophrenia. Neuroreport. 2008;19:55–8.
pubmed: 18281892 doi: 10.1097/WNR.0b013e3282f2dff6
Polgár P, Réthelyi JM, Bálint S, Komlósi S, Czobor P, Bitter I. Executive function in deficit schizophrenia: what do the dimensions of the Wisconsin Card Sorting Test tell us? Schizophr Res. 2010;122:85–93.
pubmed: 20627227 doi: 10.1016/j.schres.2010.06.007
Spalletta G, Pasini A, De Angelis F, Troisi A. Patients with deficit, nondeficit, and negative symptom schizophrenia: do they differ during episodes of acute psychotic decompensation? Schizophr Res. 1997;24:341–8.
pubmed: 9134595 doi: 10.1016/S0920-9964(96)00124-7
Yu M, Tang X, Wang X, Zhang X, Zhang X, Sha W, et al. Neurocognitive Impairments in Deficit and Non-Deficit Schizophrenia and Their Relationships with Symptom Dimensions and Other Clinical Variables. PLoS ONE. 2015;10:e0138357.
pubmed: 26381645 pmcid: 4575183 doi: 10.1371/journal.pone.0138357
Takayanagi Y, Sasabayashi D, Takahashi T, Komori Y, Furuichi A, Kido M, et al. Altered brain gyrification in deficit and non-deficit schizophrenia. Psychol Med. 2019;49:573–80.
pubmed: 29739476 doi: 10.1017/S0033291718001228
Spalletta G, De Rossi P, Piras F, Iorio M, Dacquino C, Scanu F, et al. Brain white matter microstructure in deficit and non-deficit subtypes of schizophrenia. Psychiatry Res. 2015;231:252–61.
pubmed: 25649975 doi: 10.1016/j.pscychresns.2014.12.006
Cascella NG, Fieldstone SC, Rao VA, Pearlson GD, Sawa A, Schretlen DJ. Gray-matter abnormalities in deficit schizophrenia. Schizophr Res. 2010;120:63–70.
pubmed: 20452187 doi: 10.1016/j.schres.2010.03.039
Fischer BA, Keller WR, Arango C, Pearlson GD, McMahon RP, Meyer WA, et al. Cortical structural abnormalities in deficit versus nondeficit schizophrenia. Schizophr Res. 2012;136:51–4.
pubmed: 22336954 pmcid: 3298625 doi: 10.1016/j.schres.2012.01.030
Takayanagi M, Wentz J, Takayanagi Y, Schretlen DJ, Ceyhan E, Wang L, et al. Reduced anterior cingulate gray matter volume and thickness in subjects with deficit schizophrenia. Schizophr Res. 2013;150:484–90.
pubmed: 24035178 pmcid: 4076020 doi: 10.1016/j.schres.2013.07.036
De Rossi P, Dacquino C, Piras F, Caltagirone C, Spalletta G. Left nucleus accumbens atrophy in deficit schizophrenia: A preliminary study. Psychiatry Res Neuroimaging. 2016;254:48–55.
pubmed: 27322868 doi: 10.1016/j.pscychresns.2016.06.004
Galderisi S, Quarantelli M, Volpe U, Mucci A, Cassano GB, Invernizzi G, et al. Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. Schizophr Bull. 2008;34:393–401.
pubmed: 17728266 doi: 10.1093/schbul/sbm097
Quarantelli M, Larobina M, Volpe U, Amati G, Tedeschi E, Ciarmiello A, et al. Stereotaxy-based regional brain volumetry applied to segmented MRI: validation and results in deficit and nondeficit schizophrenia. Neuroimage. 2002;17:373–84.
pubmed: 12482090 doi: 10.1006/nimg.2002.1157
Chen CH, Fiecas M, Gutiérrez ED, Panizzon MS, Eyler LT, Vuoksimaa E, et al. Genetic topography of brain morphology. Proc Natl Acad Sci USA. 2013;110:17089–94.
pubmed: 24082094 pmcid: 3801007 doi: 10.1073/pnas.1308091110
Rakic P. Evolution of the neocortex: a perspective from developmental biology. Nat Rev Neurosci. 2009;10:724–35.
pubmed: 19763105 pmcid: 2913577 doi: 10.1038/nrn2719
Panizzon MS, Fennema-Notestine C, Eyler LT, Jernigan TL, Prom-Wormley E, Neale M, et al. Distinct genetic influences on cortical surface area and cortical thickness. Cereb Cortex. 2009;19:2728–35.
pubmed: 19299253 pmcid: 2758684 doi: 10.1093/cercor/bhp026
Winkler AM, Kochunov P, Blangero J, Almasy L, Zilles K, Fox PT, et al. Cortical thickness or grey matter volume? The importance of selecting the phenotype for imaging genetics studies. Neuroimage. 2010;53:1135–46.
pubmed: 20006715 doi: 10.1016/j.neuroimage.2009.12.028
Grasby KL, Jahanshad N, Painter JN, Colodro-Conde L, Bralten J, Hibar DP, et al. The genetic architecture of the human cerebral cortex. Science. 2020;367:eaay6690.
pubmed: 32193296 pmcid: 7295264 doi: 10.1126/science.aay6690
Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44:660–9.
pubmed: 3606332 doi: 10.1001/archpsyc.1987.01800190080012
Rimol LM, Nesvåg R, Hagler DJ Jr, Bergmann O, Fennema-Notestine C, Hartberg CB, et al. Cortical volume, surface area, and thickness in schizophrenia and bipolar disorder. Biol Psychiatry. 2012;71:552–60.
pubmed: 22281121 doi: 10.1016/j.biopsych.2011.11.026
van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, et al. Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biol Psychiatry. 2018;84:644–54.
pubmed: 29960671 pmcid: 6177304 doi: 10.1016/j.biopsych.2018.04.023
Xie T, Zhang X, Tang X, Zhang H, Yu M, Gong G, et al. Mapping Convergent and Divergent Cortical Thinning Patterns in Patients With Deficit and Nondeficit Schizophrenia. Schizophr Bull. 2019;45:211–21.
pubmed: 29272543 doi: 10.1093/schbul/sbx178
Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med. 2017;36:855–75.
pubmed: 27747915 doi: 10.1002/sim.7141
Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof. 2002;25:76–97.
pubmed: 11868447 doi: 10.1177/0163278702025001006
Zugman A, Harrewijn A, Cardinale EM, Zwiebel H, Freitag GF, Werwath KE, et al. Mega-analysis methods in ENIGMA: The experience of the generalized anxiety disorder working group. Hum Brain Mapp. 2022;43:255–77.
pubmed: 32596977 doi: 10.1002/hbm.25096
Boedhoe PS, Schmaal L, Abe Y, Ameis SH, Arnold PD, Batistuzzo MC, et al. Distinct Subcortical Volume Alterations in Pediatric and Adult OCD: A Worldwide Meta- and Mega-Analysis. Am J Psychiatry. 2017;174:60–9.
pubmed: 27609241 doi: 10.1176/appi.ajp.2016.16020201
Boedhoe PSW, Schmaal L, Abe Y, Alonso P, Ameis SH, Anticevic A, et al. Cortical Abnormalities Associated With Pediatric and Adult Obsessive-Compulsive Disorder: Findings From the ENIGMA Obsessive-Compulsive Disorder Working Group. Am J Psychiatry. 2018;175:453–62.
pubmed: 29377733 doi: 10.1176/appi.ajp.2017.17050485
Radua J, Vieta E, Shinohara R, Kochunov P, Quidé Y, Green MJ, et al. Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA. Neuroimage. 2020;218:116956.
pubmed: 32470572 doi: 10.1016/j.neuroimage.2020.116956
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text rev. Washington, DC: American Psychiatric Association; 2000.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
World Health Organization. ICD-10: international statistical classification of diseases and related health problems: tenth revision, 2nd ed., World Health Organization; 2004.
First MB, Spitzer RL, Gibbon M, & Williams JBW. Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition. (SCID-I/P) New York: Biometrics Research, New York State Psychiatric Institute; 2002.
First M, Williams J, Karg R, Spitzer R. Structured Clinical Interview for DSM‐5 (SCID-5 for DSM-5) Arlington. American Psychiatric Association; 2017.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.
pubmed: 3616518 doi: 10.1093/schbul/13.2.261
Sivera R, Delingette H, Lorenzi M, Pennec X, Ayache N. A model of brain morphological changes related to aging and Alzheimer’s disease from cross-sectional assessments. Neuroimage. 2019;198:255–70.
pubmed: 31121298 doi: 10.1016/j.neuroimage.2019.05.040
Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT Jr. Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Res. 1993;47:47–56.
pubmed: 8516416 doi: 10.1016/0165-1781(93)90054-K
Goetz RR, Corcoran C, Yale S, Stanford AD, Kimhy D, Amador X, et al. Validity of a ‘proxy’ for the deficit syndrome derived from the Positive And Negative Syndrome Scale (PANSS). Schizophr Res. 2007;93:169–77.
pubmed: 17433629 pmcid: 4124591 doi: 10.1016/j.schres.2007.02.018
Kirkpatrick B, Tek C, Allardyce J, Morrison G, McCreadie RG. Summer birth and deficit schizophrenia in Dumfries and Galloway, southwestern Scotland. Am J Psychiatry. 2002;159:1382–7.
pubmed: 12153832 doi: 10.1176/appi.ajp.159.8.1382
Subotnik KL, Nuechterlein KH, Ventura J, Green MF, Hwang SS. Prediction of the deficit syndrome from initial deficit symptoms in the early course of schizophrenia. Psychiatry Res. 1998;80:53–9.
pubmed: 9727963 doi: 10.1016/S0165-1781(98)00052-3
Kirkpatrick B, Amador XF, Flaum M, Yale SA, Gorman JM, Carpenter WT Jr, et al. The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophr Res. 1996;20:69–77.
pubmed: 8794495 doi: 10.1016/0920-9964(95)00102-6
Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968–80.
pubmed: 16530430 doi: 10.1016/j.neuroimage.2006.01.021
van Erp TG, Hibar DP, Rasmussen JM, Glahn DC, Pearlson GD, Andreassen OA, et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry. 2016;21:547–53.
pubmed: 26033243 doi: 10.1038/mp.2015.63
Sowell ER, Peterson BS, Thompson PM, Welcome SE, Henkenius AL, Toga AW. Mapping cortical change across the human life span. Nat Neurosci. 2003;6:309–15.
pubmed: 12548289 doi: 10.1038/nn1008
Borenstein M. Software for Publication Bias. In: Publication Bias in Meta‐Analysis: Prevention, Assessment and Adjustments. 2005:193–220.
Rakic P. A small step for the cell, a giant leap for mankind: a hypothesis of neocortical expansion during evolution. Trends Neurosci. 1995;18:383–8.
pubmed: 7482803 doi: 10.1016/0166-2236(95)93934-P
Wierenga LM, Langen M, Oranje B, Durston S. Unique developmental trajectories of cortical thickness and surface area. Neuroimage. 2014;87:120–6.
pubmed: 24246495 doi: 10.1016/j.neuroimage.2013.11.010
Pontious A, Kowalczyk T, Englund C, Hevner RF. Role of intermediate progenitor cells in cerebral cortex development. Dev Neurosci. 2008;30:24–32.
pubmed: 18075251 doi: 10.1159/000109848
Birnbaum R, Weinberger DR. Genetic insights into the neurodevelopmental origins of schizophrenia. Nat Rev Neurosci. 2017;18:727–40.
pubmed: 29070826 doi: 10.1038/nrn.2017.125
Yildiz M, Borgwardt SJ, Berger GE. Parietal lobes in schizophrenia: do they matter? Schizophr Res Treat. 2011;2011:581686.
Spence SA, Brooks DJ, Hirsch SR, Liddle PF, Meehan J, Grasby PM. A PET study of voluntary movement in schizophrenic patients experiencing passivity phenomena (delusions of alien control). Brain. 1997;120:1997–2011.
pubmed: 9397017 doi: 10.1093/brain/120.11.1997
Yang YL, Joshi AA, Joshi SH, Baker LA, Narr KL, Raine A, et al. Genetic and environmental influences on cortical thickness among 14-year-old twins. Neuroreport. 2012;23:702–6.
pubmed: 22713927 pmcid: 3675224 doi: 10.1097/WNR.0b013e328355a62a
Antonova E, Sharma T, Morris R, Kumari V. The relationship between brain structure and neurocognition in schizophrenia: a selective review. Schizophr Res. 2004;70:117–45.
pubmed: 15329292 doi: 10.1016/j.schres.2003.12.002
Jonides J, Schumacher EH, Smith EE, Koeppe RA, Awh E, Reuter-Lorenz PA, et al. The role of parietal cortex in verbal working memory. J Neurosci. 1998;18:5026–34.
pubmed: 9634568 pmcid: 6792554 doi: 10.1523/JNEUROSCI.18-13-05026.1998
Rushworth MFS, Ellison A, Walsh V. Complementary localization and lateralization of orienting and motor attention (vol 4, pg 656, 2001). Nat Neurosci. 2001;4:959–959.
doi: 10.1038/88492
Thoenissen D, Zilles K, Toni I. Differential involvement of parietal and precentral regions in movement preparation and motor intention. J Neurosci. 2002;22:9024–34.
pubmed: 12388609 pmcid: 6757678 doi: 10.1523/JNEUROSCI.22-20-09024.2002
Gottlieb J. From thought to action: the parietal cortex as a bridge between perception, action, and cognition. Neuron. 2007;53:9–16.
pubmed: 17196526 doi: 10.1016/j.neuron.2006.12.009
Buckner RL, Wheeler ME. The cognitive neuroscience of remembering. Nat Rev Neurosci. 2001;2:624–34.
pubmed: 11533730 doi: 10.1038/35090048
Bor D, Seth AK. Consciousness and the prefrontal parietal network: insights from attention, working memory, and chunking. Front Psychol. 2012;3:63.
pubmed: 22416238 pmcid: 3298966 doi: 10.3389/fpsyg.2012.00063
Lou HC, Changeux JP, Rosenstand A. Towards a cognitive neuroscience of self-awareness. Neurosci Biobehav Rev. 2017;83:765–73.
pubmed: 27079562 doi: 10.1016/j.neubiorev.2016.04.004
Cuffel BJ, Alford J, Fischer EP, Owen RR. Awareness of illness in schizophrenia and outpatient treatment adherence. J Nerv Ment Dis. 1996;184:653–9.
pubmed: 8955677 doi: 10.1097/00005053-199611000-00001
Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J, Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev. 2011;35:573–88.
pubmed: 20620163 doi: 10.1016/j.neubiorev.2010.07.001
Green MF, Olivier B, Crawley JN, Penn DL, Silverstein S. Social cognition in schizophrenia: recommendations from the measurement and treatment research to improve cognition in schizophrenia new approaches conference. Schizophr Bull. 2005;31:882–7.
pubmed: 16135561 doi: 10.1093/schbul/sbi049
Schwartz RC. The relationship between insight, illness and treatment outcome in schizophrenia. Psychiatr Q. 1998;69:1–22.
pubmed: 9536472 doi: 10.1023/A:1022141322657
Hartikainen KM. Emotion-Attention Interaction in the Right Hemisphere. Brain Sci. 2021;11:1006.
pubmed: 34439624 pmcid: 8394055 doi: 10.3390/brainsci11081006
Mitchell RL, Crow TJ. Right hemisphere language functions and schizophrenia: the forgotten hemisphere? Brain. 2005;128:963–78.
pubmed: 15743870 doi: 10.1093/brain/awh466
Blom SSAH, Aarts H, Semin GR. Lateralization of facial emotion processing and facial mimicry. Laterality. 2020;25:259–74.
pubmed: 31464163 doi: 10.1080/1357650X.2019.1657127
Parola A, Brasso C, Morese R, Rocca P, Bosco FM. Understanding communicative intentions in schizophrenia using an error analysis approach (vol 7, 12, 2021). Npj Schizophr. 2021;7:12.
pubmed: 33637736 pmcid: 7910544 doi: 10.1038/s41537-021-00142-7
Snelleksz M, Rossell SL, Gibbons A, Nithianantharajah J, Dean B. Evidence that the frontal pole has a significant role in the pathophysiology of schizophrenia. Psychiat Res. 2022;317:114850.
doi: 10.1016/j.psychres.2022.114850
Salvador R, Suckling J, Coleman MR, Pickard JD, Menon D, Bullmore ET. Neurophysiological architecture of functional magnetic resonance images of human brain. Cereb Cortex. 2005;15:1332–42.
pubmed: 15635061 doi: 10.1093/cercor/bhi016
Hunter R, Barry S. Negative symptoms and psychosocial functioning in schizophrenia: Neglected but important targets for treatment. Eur Psychiat. 2012;27:432–6.
doi: 10.1016/j.eurpsy.2011.02.015
Allen P, Moore H, Corcoran CM, Gilleen J, Kozhuharova P, Reichenberg A, et al. Emerging Temporal Lobe Dysfunction in People at Clinical High Risk for Psychosis. Front Psychiatry. 2019;10:298.
pubmed: 31133894 pmcid: 6526750 doi: 10.3389/fpsyt.2019.00298
Borgwardt SJ, McGuire PK, Aston J, Gschwandtner U, Pflüger MO, Stieglitz RD, et al. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr Res. 2008;106:108–14.
pubmed: 18789654 doi: 10.1016/j.schres.2008.08.007
Tohid H, Faizan M, Faizan U. Alterations of the occipital lobe in schizophrenia. Neurosci (Riyadh). 2015;20:213–24.
Vanes LD, Mouchlianitis E, Patel K, Barry E, Wong K, Thomas M, et al. Neural correlates of positive and negative symptoms through the illness course: an fMRI study in early psychosis and chronic schizophrenia. Sci Rep. 2019;9:14444.
pubmed: 31595009 pmcid: 6783468 doi: 10.1038/s41598-019-51023-0
Hogstrom LJ, Westlye LT, Walhovd KB, Fjell AM. The structure of the cerebral cortex across adult life: age-related patterns of surface area, thickness, and gyrification. Cereb Cortex. 2013;23:2521–30.
pubmed: 22892423 doi: 10.1093/cercor/bhs231
Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci. 2000;4:215–22.
pubmed: 10827444 doi: 10.1016/S1364-6613(00)01483-2
Davis KD, Taylor KS, Hutchison WD, Dostrovsky JO, McAndrews MP, Richter EO, et al. Human anterior cingulate cortex neurons encode cognitive and emotional demands. J Neurosci. 2005;25:8402–6.
pubmed: 16162922 pmcid: 6725669 doi: 10.1523/JNEUROSCI.2315-05.2005
Horne CM, Sahni A, Pang SW, Vanes LD, Szentgyorgyi T, Averbeck B, et al. The role of cognitive control in the positive symptoms of psychosis. Neuroimage Clin. 2022;34:103004.
pubmed: 35468567 pmcid: 9059151 doi: 10.1016/j.nicl.2022.103004
Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30:119–23.
pubmed: 2616682 doi: 10.1016/0165-1781(89)90153-4
Fervaha G, Agid O, Foussias G, Siddiqui I, Takeuchi H, Remington G. Neurocognitive impairment in the deficit subtype of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2016;266:397–407.
pubmed: 26260899 doi: 10.1007/s00406-015-0629-6
Messias E, Kirkpatrick B, Bromet E, Ross D, Buchanan RW, Carpenter WT Jr, et al. Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. Arch Gen Psychiatry. 2004;61:985–9.
pubmed: 15466671 doi: 10.1001/archpsyc.61.10.985
Schmaal L, Hibar DP, Sämann PG, Hall GB, Baune BT, Jahanshad N, et al. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. Mol Psychiatry. 2017;22:900–9.
pubmed: 27137745 doi: 10.1038/mp.2016.60

Auteurs

Nerisa Banaj (N)

Neuropsychiatry Laboratory, Department of Clinical Neuroscience and Neurorehabilitation, IRCCS Santa Lucia Foundation, Rome, Italy. n.banaj@hsantalucia.it.

Daniela Vecchio (D)

Neuropsychiatry Laboratory, Department of Clinical Neuroscience and Neurorehabilitation, IRCCS Santa Lucia Foundation, Rome, Italy.

Fabrizio Piras (F)

Neuropsychiatry Laboratory, Department of Clinical Neuroscience and Neurorehabilitation, IRCCS Santa Lucia Foundation, Rome, Italy.

Pietro De Rossi (P)

Child and Adolescence Neuropsychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Juan Bustillo (J)

Psichiatry and Neuroscience, University of New Mexico, Albuquerque, NM, USA.

Simone Ciufolini (S)

Psychosis Studies, Institute of Psychiatry, Psychology and Neurology, King's College London, London, UK.

Paola Dazzan (P)

Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neurology, King's College London, London, UK.

Marta Di Forti (M)

Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neurology, King's College London, London, UK.

Erin W Dickie (EW)

Center for Addiction and Mental Health, Campbell Family Mental Health Research Institute, Toronto, ON, Canada.
Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Kimel Family Lab, Centre for Addiction and Mental Health, Toronto, ON, Canada.

Judith M Ford (JM)

San Francisco VA Health Care System, San Francisco, CA, USA.
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA.

Paola Fuentes-Claramonte (P)

FIMDAG Sisters Hospitallers Research Foundation, Barcelona, Spain.
Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.

Oliver Gruber (O)

Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University, Heidelberg, Baden-Wuerttemberg, Germany.

Amalia Guerrero-Pedraza (A)

Hospital Benito Menni CASM, Barcelona, Spain.

Holly K Hamilton (HK)

San Francisco VA Health Care System, San Francisco, CA, USA.
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA.

Fleur M Howells (FM)

Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, Western Cape, South Africa.

Bernd Kraemer (B)

Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University, Heidelberg, Baden-Wuerttemberg, Germany.

Stephen M Lawrie (SM)

Division of Psychiatry, University of Edinburgh, Edinburg, EH10 5HF, UK.

Daniel H Mathalon (DH)

San Francisco VA Health Care System, San Francisco, CA, USA.
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA.

Robin Murray (R)

Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neurology, King's College London, London, UK.

Edith Pomarol-Clotet (E)

FIMDAG Sisters Hospitallers Research Foundation, Barcelona, Spain.
Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.

Steven G Potkin (SG)

Department of Psychiatry, University of California Irvine, Newfoundland, NJ, NJ 07435, USA.

Adrian Preda (A)

Psychiatry and Human Behavior, University of California Irvine, Orange, CA, 92868, USA.

Joaquim Radua (J)

Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain.
Imaging of mood- and anxiety-related disorders (IMARD), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, 08036, Spain.
Medicina, University of Barcelona, Barcelona, 08036, Spain.

Anja Richter (A)

Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University, Heidelberg, Baden-Wuerttemberg, Germany.

Raymond Salvador (R)

FIMDAG Sisters Hospitallers Research Foundation, Barcelona, Spain.

Akira Sawa (A)

Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Genetic Medicine, Johns Hopkins University School of Medicine Baltimore, Baltimore, MD, USA.
Department of Pharmacology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Freda Scheffler (F)

Department of Psychiatry and Mental Health, Neuroscience Institute, University of Cape Town, Cape Town, South Africa.
Brain Behavior Unit, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.

Kang Sim (K)

West Region, Institute of Mental Health, National Healthcare Group, Singapore, Singapore.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

Filip Spaniel (F)

CARE, National Institute of Mental Health, Klecany, Czech Republic.

Dan J Stein (DJ)

SAMRC Unit on Risk & Resilience in Mental Disorders, Department of Psychiatry & Neuroscience Institute, University of Cape Town, Cape Town, South Africa.

Henk S Temmingh (HS)

Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, Western Cape, South Africa.
Department of Psychiatry and Mental Health, Valkenberg Psychiatric Hospital, Cape Town, Western Cape, South Africa.

Sophia I Thomopoulos (SI)

Imaging Genetics Center, Mark & Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA.

David Tomecek (D)

CARE, National Institute of Mental Health, Klecany, Czech Republic.

Anne Uhlmann (A)

Department of child and adolescent psychiatry, TU Dresden, Dresden, Saxony, Germany.

Aristotle Voineskos (A)

Center for Addiction and Mental Health, Campbell Family Mental Health Research Institute, Toronto, ON, Canada.
Department of Psychiatry, University of Toronto, Temerty Faculty of Medicine, Toronto, ON, Canada.

Kun Yang (K)

Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Neda Jahanshad (N)

Imaging Genetics Center, Mark & Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA.

Paul M Thompson (PM)

Imaging Genetics Center, Mark & Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA.

Theo G M Van Erp (TGM)

Clinical Translational Neuroscience Laboratory, Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, CA, USA.
Center for the Neurobiology of Learning and Memory, University of California Irvine, Irvine, CA, USA.

Jessica A Turner (JA)

Department of Psychiatry and Behavioral Health, Wexner Medical Center, The Ohio State University, Columbus, OH, USA.

Gianfranco Spalletta (G)

Neuropsychiatry Laboratory, Department of Clinical Neuroscience and Neurorehabilitation, IRCCS Santa Lucia Foundation, Rome, Italy.
Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.

Federica Piras (F)

Neuropsychiatry Laboratory, Department of Clinical Neuroscience and Neurorehabilitation, IRCCS Santa Lucia Foundation, Rome, Italy.

Classifications MeSH